EP1309718A4 - Neutrokin-alpha und spleiss-varianten von neutrokin-alpha - Google Patents

Neutrokin-alpha und spleiss-varianten von neutrokin-alpha

Info

Publication number
EP1309718A4
EP1309718A4 EP01967981A EP01967981A EP1309718A4 EP 1309718 A4 EP1309718 A4 EP 1309718A4 EP 01967981 A EP01967981 A EP 01967981A EP 01967981 A EP01967981 A EP 01967981A EP 1309718 A4 EP1309718 A4 EP 1309718A4
Authority
EP
European Patent Office
Prior art keywords
neutrokin
alpha
splice variants
splice
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01967981A
Other languages
English (en)
French (fr)
Other versions
EP1309718A2 (de
Inventor
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Stephen Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1309718A2 publication Critical patent/EP1309718A2/de
Publication of EP1309718A4 publication Critical patent/EP1309718A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rehabilitation Therapy (AREA)
EP01967981A 2000-08-15 2001-08-15 Neutrokin-alpha und spleiss-varianten von neutrokin-alpha Withdrawn EP1309718A4 (de)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US22562800P 2000-08-15 2000-08-15
US225628P 2000-08-15
US22700800P 2000-08-23 2000-08-23
US227008P 2000-08-23
US23433800P 2000-09-22 2000-09-22
US234338P 2000-09-22
US24080600P 2000-10-17 2000-10-17
US240806P 2000-10-17
US25002000P 2000-11-30 2000-11-30
US250020P 2000-11-30
US27624801P 2001-03-16 2001-03-16
US276248P 2001-03-16
US29349901P 2001-05-25 2001-05-25
US293499P 2001-05-25
US29612201P 2001-06-07 2001-06-07
US296122P 2001-06-07
US30480901P 2001-07-13 2001-07-13
US304809P 2001-07-13
PCT/US2001/025549 WO2002018620A2 (en) 2000-08-15 2001-08-15 Neutrokine-alpha and neutrokine-alpha splice variant

Publications (2)

Publication Number Publication Date
EP1309718A2 EP1309718A2 (de) 2003-05-14
EP1309718A4 true EP1309718A4 (de) 2004-08-25

Family

ID=27578713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01967981A Withdrawn EP1309718A4 (de) 2000-08-15 2001-08-15 Neutrokin-alpha und spleiss-varianten von neutrokin-alpha

Country Status (4)

Country Link
EP (1) EP1309718A4 (de)
AU (1) AU2001288260A1 (de)
CA (1) CA2419661A1 (de)
WO (1) WO2002018620A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
BR0007719A (pt) 1999-01-25 2001-11-13 Biogen Inc Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
UA75049C2 (uk) 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1507793A4 (de) * 2001-10-17 2006-02-01 Human Genome Sciences Inc Neutrokin-alpha und neutrokin-alpha-spleissvariante
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
CA2523776A1 (en) * 2003-03-07 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
NZ583905A (en) 2004-10-13 2011-12-22 Univ Washington Use of BAFF to Treat Sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035170A2 (en) * 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROT [online] 16 October 2001 (2001-10-16), "Tumor necrosis factor ligand superfamily member 13B", XP002286038, retrieved from UNIPROT Database accession no. Q9Y275 *
DENARDO G L ET AL: "Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts", CLINICAL CANCER RESEARCH 1998 UNITED STATES, vol. 4, no. 10, 1998, pages 2483 - 2490, XP001181898, ISSN: 1078-0432 *
HEPPELER A ET AL: "RECEPTOR TARGETING FOR TUMOR LOCALISATION AND THERAPY WITH RADIOPEPTIDES", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 9, no. 7, 2000, pages 971 - 994, XP000982225, ISSN: 0929-8673 *
KARPUSAS M ET AL: "Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 315, no. 5, 1 February 2002 (2002-02-01), pages 1145 - 1154, XP004470833, ISSN: 0022-2836 *
LIU YINGFANG ET AL: "Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands", CELL, vol. 108, no. 3, 8 February 2002 (2002-02-08), pages 383 - 394, XP002286032, ISSN: 0092-8674 *
MOORE P A ET AL: "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 285, no. 5425, 9 July 1999 (1999-07-09), pages 260 - 263, XP002142252, ISSN: 0036-8075 *
OREN DEENA A ET AL: "Structural basis of BLyS receptor recognition.", NATURE STRUCTURAL BIOLOGY, vol. 9, no. 4, April 2002 (2002-04-01), pages 288 - 292, XP002286033, ISSN: 1072-8368 (ISSN print) *
SCHNEIDER P ET AL: "BAFF, A NOVEL LIGAND OF THE TUMOR NECROSIS FACTOR FAMILY, STIMULATES B CELL GROWTH", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747 - 1756, XP000915409, ISSN: 0022-1007 *
SHU H-B ET AL: "TALL-1 IS A NOVEL MEMBER OF THE TNF FAMILY THAT IS DOWN-REGULATED BY MITOGENS", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 65, no. 5, May 1999 (1999-05-01), pages 680 - 683, XP000939092, ISSN: 0741-5400 *
YU G ET AL: "APRIL AND TALL-I AND RECEPTORS BCMA AND TACI: SYSTEM FOR REGULATING HUMORAL IMMUNITY", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 1, no. 3, September 2000 (2000-09-01), pages 252 - 256, XP000982268, ISSN: 1529-2908 *

Also Published As

Publication number Publication date
AU2001288260A1 (en) 2002-03-13
WO2002018620A3 (en) 2003-03-20
CA2419661A1 (en) 2002-03-07
EP1309718A2 (de) 2003-05-14
WO2002018620A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
EP1309718A4 (de) Neutrokin-alpha und spleiss-varianten von neutrokin-alpha
DE50112013D1 (de) Deodorantien und antiperspirantien
EP1412378A4 (de) Aptamere und antiaptamere
DE60030541D1 (de) Leuchte und leuchttafeln
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
DE50105915D1 (de) Schutzhülle
DE69924155D1 (de) Fluoren-copolymere und daraus hergestellte vorrichtungen
EP1298180A4 (de) Hydrophobe und lipophobe zusammensetzung
DE50100900D1 (de) Fixierelement
ATE264960T1 (de) Paneelanordnung und verbindungsmittel
NO20030795L (no) Kinazolinderivater
ID26599A (id) Turunan triazola dan imidazola
NO20030917D0 (no) Anvendelse
DE10085449T1 (de) Fixiervorrichtung
EP1162876A4 (de) Zusammenlegbare und zusammenklappbare strukturen
DE60029075D1 (de) Kopiergerät und Kopierverfahren
DE60021954D1 (de) Polarisierendes Element und optisches Element
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
DE60028486D1 (de) Videocoder und -decoder
DE50010446D1 (de) Emulsionen
DE50009766D1 (de) Befestigungs- und Fixierungsvorrichtung
DE60007360T2 (de) Amorphe modifikation von torasemid
NO20024617D0 (no) Aryl- og heteroarylsulfonater
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DE60125959D1 (de) Unterscheidung zwischen gnrh-i und gnrh-ii

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030305

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/64 B

Ipc: 7C 12N 15/63 B

Ipc: 7C 12N 15/62 B

Ipc: 7C 12N 15/13 B

Ipc: 7C 12N 15/12 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 07K 1/24 B

Ipc: 7C 07K 16/18 B

Ipc: 7C 07K 16/00 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/395 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040715

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 51/08 B

Ipc: 7A 61K 38/19 B

Ipc: 7C 07K 14/705 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060113